Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (241-250 of 491) with videos related to

Pageof 50
Sort By:
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
Contemporary Oncology (Poznan, Poland)|January 26, 2022
Mutational landscape of primary and recurrent Ewing sarcomaPaulina Jagodzińska-Mucha, Paweł Sobczuk, Michał Mikuła, et al.
Cancers|September 28, 2023
Mesenchymal Chondrosarcoma from Diagnosis to Clinical TrialsMonika Dudzisz-Śledź, Monika Kondracka, Monika Rudzińska, et al.
Annals of Surgery|December 19, 2008
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodesAlexander C J van Akkooi, Zbigniew I Nowecki, Christiane Voit, et al.
Journal of Cancer Research and Clinical Oncology|April 27, 2007
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)Piotr Rutkowski, Zbigniew I Nowecki, Maria Debiec-Rychter, et al.
International Journal of Molecular Sciences|May 28, 2022
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" TrialChe-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Annals of Surgical Oncology|May 3, 2007
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorPiotr Rutkowski, Zbigniew I Nowecki, Wanda Michej, et al.
Cancer|June 6, 2024
Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr J Błoński, et al.
BMC Cancer|December 1, 2009
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expressionJerzy Ostrowski, Marcin Polkowski, Agnieszka Paziewska, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2021
Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical TrialMateusz J Spałek, Hanna Koseła-Paterczyk, Aneta Borkowska, et al.
Pageof 50

Showing results (241-250 of 491) with videos related to

Sort By:
Pageof 50
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
Contemporary Oncology (Poznan, Poland)|January 26, 2022
Mutational landscape of primary and recurrent Ewing sarcomaPaulina Jagodzińska-Mucha, Paweł Sobczuk, Michał Mikuła, et al.
Cancers|September 28, 2023
Mesenchymal Chondrosarcoma from Diagnosis to Clinical TrialsMonika Dudzisz-Śledź, Monika Kondracka, Monika Rudzińska, et al.
Annals of Surgery|December 19, 2008
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodesAlexander C J van Akkooi, Zbigniew I Nowecki, Christiane Voit, et al.
Journal of Cancer Research and Clinical Oncology|April 27, 2007
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)Piotr Rutkowski, Zbigniew I Nowecki, Maria Debiec-Rychter, et al.
International Journal of Molecular Sciences|May 28, 2022
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" TrialChe-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Annals of Surgical Oncology|May 3, 2007
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorPiotr Rutkowski, Zbigniew I Nowecki, Wanda Michej, et al.
Cancer|June 6, 2024
Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr J Błoński, et al.
BMC Cancer|December 1, 2009
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expressionJerzy Ostrowski, Marcin Polkowski, Agnieszka Paziewska, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2021
Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical TrialMateusz J Spałek, Hanna Koseła-Paterczyk, Aneta Borkowska, et al.
Pageof 50